Seer Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Full Year 2022 Outlook

Rhea-AI Summary

Seer, Inc. (Nasdaq: SEER) reported a significant increase in revenue for the full year 2021, totaling $6.6 million, driven by the successful launch of the Proteograph Product Suite. The fourth quarter alone saw revenue of $3.1 million, up from $336 thousand in Q4 2020. However, the company faced a net loss of $19.7 million in the fourth quarter and $71.2 million for the full year. For 2022, Seer anticipates revenue of $14.0 million to $16.0 million while increasing investments in commercial and R&D activities.

Positive

• Revenue growth: $6.6 million in 2021 vs. $656 thousand in 2020.
• Successful launch of the Proteograph Product Suite with multiple pre-booked orders.
• Gross margin improvement: 52% for full year 2021.

Negative

• Net loss increased to $71.2 million for 2021 from $32.8 million in 2020.
• Operating expenses significantly rose to $74.9 million for 2021, up from $34.3 million.

Demonstrated tangible market progress and shipped 17 instruments through year end 2021

REDWOOD CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2021.

“This has been a momentous year for Seer, one that paved the way for our technology in the hands of lighthouse collaborators and customers, demonstrated the unique benefits of our technology, and positioned Seer to open up new possibilities for researchers with an unbiased, scalable approach to proteomics,” said Omid Farokhzad, Chief Executive Officer and Chair, “As we enter 2022, we are excited about our market opportunity, confident in what the Proteograph Product Suite can deliver and ready to serve an expanding customer base as we move forward with broad commercial release of the Proteograph.”

Recent Highlights

• Revenue of $6.6 million for the full year 2021, inclusive of $3.1 million for the fourth quarter
• Commenced broad commercial release of the Proteograph Product Suite, with multiple orders pre-booked
• Created the Proteogenomics Consortium with Discovery Life Sciences and SCIEX in January 2022, a first-of-its-kind, multi-year collaboration for large-scale studies, to offer deep, unbiased proteomics with capacity ramping to over 100,000 samples per year
• Launched the Centers of Excellence program with providers in North America, Europe, and Asia Pacific
• Added Meeta Gulyani, Head of Strategy, Business Development and Transformation for the Life Science business of Merck KGaA, Darmstadt, Germany and Rachel Haurwitz, Ph.D, CEO of Caribou Biosciences, to the Board of Directors
  

Fourth Quarter 2021 Financial Results

Revenue was $3.1 million for the three months ended December 31, 2021, as compared to $336 thousand for the three months ended December 31, 2020. The increase was the result of increased sales of the Proteograph Product Suite, including SP100 instruments, consumable kits and product evaluations in the fourth of quarter of 2021. Product-related revenue was $3.0 million, including $1.2 million of related party revenue, and grant revenue was $34 thousand.

Gross profit, inclusive of grant revenue, was $1.4 million and gross margin was 47% for the fourth quarter of 2021.

Operating expenses were $21.3 million for the fourth quarter of 2021, as compared to $13.4 million for the corresponding prior year period. The increase in expenses was driven by increased employee compensation and other related expenses, including stock-based compensation and increased costs related to being a publicly traded company.

Net loss was $19.7 million for the fourth quarter of 2021, as compared to $12.9 million for the corresponding prior year period.

Full Year 2021 Financial Results

Revenue was $6.6 million for the year ended December 31, 2021, as compared to $656 thousand for the year ended December 31, 2020. Product-related revenue was $5.9 million, including $2.3 million of related party revenue, service revenue was $500 thousand and grant and other revenue was $223 thousand.

Gross profit, inclusive of grant revenue, was $3.4 million and gross margin was 52% for the full year 2021.

Operating expenses were $74.9 million for the full year 2021, as compared to $34.3 million for the corresponding prior year period.

Net loss was $71.2 million for the full year 2021, as compared to $32.8 million for the corresponding prior year period.

Cash, cash equivalents and investments were $493.3 million as of December 31, 2021.

2022 Guidance

Seer expects full year 2022 revenue to be in the range of $14.0 million to $16.0 million. In 2022, Seer also expects to continue to increase investments in its commercial, operations and research and development activities in order to drive long-term growth and value creation.

Webcast Information

Seer will host a conference call to discuss the fourth quarter and full year 2021 financial results on Monday, February 28, 2022 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at http://investor.seer.bio. The webcast will be archived and available for replay for at least 90 days after the event.

About Seer

Seer™ is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that reflect the Company’s current views with respect to certain current and future events and financial performance. Words such as “expects,” “anticipates,” “projects,” “intends,” “plans,” “believes,” “estimates,” variations of such words, and similar expressions are also intended to identify such forward-looking statements. Such forward-looking statements are based on the Company’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements, including but not limited to statements regarding the Company’s outlook for fiscal year 2022 and its ability to imagine and pioneer new ways to decode the secrets of the proteome to improve human health. These and other risks are described more fully in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 10-K, to be filed with the SEC on March 1, 2022, and other documents the Company subsequently files with the SEC from time to time. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact:
Carrie Mendivil
investor@seer.bio

Media Contact:
Karen Possemato
pr@seer.bio

Seer, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
(Unaudited)

	Three Months Ended December 31,								Year Ended December 31,
		2021				2020				2021				2020
Revenue:
Product	$	1,882			$	—			$	3,577			$	—
Service		—				—				500				—
Related party		1,150				—				2,317				—
Grant and other		34				336				223				656
Total revenue		3,066				336				6,617				656
Cost of revenue:
Product		1,222				—				2,300				—
Service		—				—				42				—
Related party		411				—				863				—
Total cost of revenue		1,633				—				3,205				—
Gross profit		1,433				336				3,412				656
Operating expenses:
Research and development		8,215				5,422				29,121				18,942
Selling, general and administrative		13,092				7,955				45,764				15,363
Total operating expenses		21,307				13,377				74,885				34,305
Loss from operations		(19,874	)			(13,041	)			(71,473	)			(33,649	)
Other income (expense):
Interest income		157				105				326				883
Interest expense		(22	)			—				(22	)			—
Other expense		—				—				—				(9	)
Total other income		135				105				304				874
Net loss	$	(19,739	)		$	(12,936	)		$	(71,169	)		$	(32,775	)
Net loss per share attributable to common stockholders, basic and diluted	$	(0.32	)		$	(0.54	)		$	(1.17	)		$	(2.48	)
Weighted-average common shares outstanding, basic and diluted		61,562,065				23,893,201				60,863,950				13,216,657

Seer, Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share amounts)
(Unaudited)

	December 31,
		2021				2020
ASSETS
Current assets:
Cash and cash equivalents	$	232,813			$	333,585
Short-term investments		167,261				98,278
Accounts receivable, net		2,495				—
Related party receivables		1,283				99
Other receivables		366				163
Inventory		4,145				551
Prepaid expenses and other current assets		3,336				452
Total current assets		411,699				433,128
Long-term investments		93,186				—
Operating lease right-of-use assets		20,142				—
Property and equipment, net		13,087				8,441
Restricted cash		524				343
Other assets		501				407
Total assets	$	539,139			$	442,319
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	3,789			$	2,115
Accrued expenses		7,371				5,147
Accrued research and development		1,023				396
Deferred revenue		376				250
Deferred rent, current		—				186
Operating lease liabilities, current		864				—
Total current liabilities		13,423				8,094
Deferred rent, net of current portion		—				1,899
Operating lease liabilities, net of current portion		22,459				—
Other noncurrent liabilities		341				717
Total liabilities		36,223				10,710
Stockholders’ equity:
Preferred stock, $0.00001 par value; 5,000,000 shares authorized as of December 31, 2021 and 2020; zero shares issued and outstanding as of December 31, 2021 and 2020		—				—
Class A common stock, $0.00001 par value; 94,000,000 shares authorized as of December 31, 2021 and 2020; 57,493,005 and 53,395,319 shares issued and outstanding as of December 31, 2021 and 2020, respectively;		1				1
Class B common stock, $0.00001 par value; 6,000,000 shares authorized as of December 31, 2021 and 2020; 4,522,478 and 5,865,732 shares issued and outstanding as of December 31, 2021 and 2020, respectively;		—				—
Additional paid-in capital		629,981				486,915
Accumulated other comprehensive income (loss)		(536	)			54
Accumulated deficit		(126,530	)			(55,361	)
Total stockholders’ equity		502,916				431,609
Total liabilities and stockholders’ equity	$	539,139			$	442,319

 

FAQ

What were Seer, Inc.'s revenue results for 2021?

Seer, Inc. reported revenue of $6.6 million for the full year 2021.

What is Seer, Inc.'s expected revenue guidance for 2022?

Seer expects full year 2022 revenue to be in the range of $14.0 million to $16.0 million.

How did Seer, Inc.'s Q4 2021 revenue compare to Q4 2020?

Q4 2021 revenue was $3.1 million, significantly up from $336 thousand in Q4 2020.

What was Seer, Inc.'s net loss for the fourth quarter of 2021?

Seer reported a net loss of $19.7 million for the fourth quarter of 2021.

What contributed to the increase in Seer, Inc.'s operating expenses in 2021?

Operating expenses rose due to increased employee compensation and costs related to being publicly traded, totaling $74.9 million.